{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-061989","form_type":"8-K","ticker":"SPRY","cik":"0001671858","company_name":"ARS Pharmaceuticals, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.010833+00:00","generated_at":"2026-06-08T06:57:31.759394+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ARS Pharmaceuticals Q3 net loss $14.9M; neffy NDA resubmission anticipated H1 2024","bullets":["Cash, equivalents and short-term investments $241.9M as of Sep 30, 2023; operating runway ≥3 years.","Net loss $14.9M for Q3 2023; R&D $3.0M, G&A $15.0M.","FDA issued Complete Response Letter in Sep 2023 for neffy; repeat-dose study topline expected Q1 2024.","NDA resubmission planned H1 2024; potential U.S. launch in H2 2024 if approved.","European MAA decision expected Q2 2024; positive clinical results published in JACI."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-061989","json":"https://secwatch.observer/filing/0000950170-23-061989.json","markdown":"https://secwatch.observer/filing/0000950170-23-061989.md","text":"https://secwatch.observer/filing/0000950170-23-061989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023061989/0000950170-23-061989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023061989/spry-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:57:31.759394+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d621616873bb512680f329b3290c320c264dac79","claim":"ARS Pharmaceuticals, Inc. reported three and nine months ended September 30, 2023 results: net income Net loss was $14.9 million for the quarter ended September 30, 2023..","evidence_excerpt":"ARS Pharmaceuticals, Inc. (the “Company”) announced its financial results for the three and nine months ended September 30, 2023 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1671858/000095017023061989/0000950170-23-061989-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Net income","value":"Net loss was $14.9 million for the quarter ended September 30, 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}